<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659110</url>
  </required_header>
  <id_info>
    <org_study_id>cycdc2018-1</org_study_id>
    <nct_id>NCT03659110</nct_id>
  </id_info>
  <brief_title>Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice</brief_title>
  <official_title>Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chaoyang District Centre for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chaoyang District Centre for Disease Control and Prevention</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-Approval Safety Monitoring Program to assess the safety profile of GARDASIL in
      china usual practice.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Rate of Adverse reactions of GARDASIL in China usual practice</measure>
    <time_frame>24 months</time_frame>
    <description>Adverse reactions associated with vaccine will be observed in females Aged 20-45 Years after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events following any dose of vaccine</measure>
    <time_frame>within 30 days after each dose</time_frame>
    <description>Number of participants with adverse events following any dose of vaccine</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>1000 subjects receive the HPV 4 vaccine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV 4</intervention_name>
    <description>1000 subjects will be received the HPV 4 vaccine</description>
    <arm_group_label>1000 subjects receive the HPV 4 vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Volunteers aged 20-45 years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any person who is intended to be inoculated with first dose GARDASIL based on his/her
             own wishes at screening

        Exclusion Criteria:

          1. Unable to provide written informed consent

          2. Any woman who is known being pregnant at screening

          3. Subject who is participating or going to participate in another study which involves
             GARDASIL administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

